| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Clinical Transplantation |



,¶
Divisions of* Nephrology; and
Nuclear Medicine, Department of Medicine, University of Ottawa;
Kidney Research Centre; and ¶ Clinical Epidemiology Program, The Ottawa Health Research Institute;
Division of Nephrology, Department of Pediatrics; and || Department of Laboratory Medicine, Childrens Hospital of Eastern Ontario and the University of Ottawa, Ottawa, Ontario, Canada
Address correspondence to: Dr. Greg A. Knoll, Division of Nephrology, The Ottawa Hospital, Riverside Campus, 1967 Riverside Drive, Ottawa, Ontario, Canada K1H 7W9. Phone: 613-738-8400; Fax: 613-738-8337; gknoll{at}ottawahospital.on.ca
Received for publication May 16, 2005. Accepted for publication September 2, 2005.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
The limitations of serum creatinine and urinary creatinine clearance for estimation of estimating GFR are well known (3,4). Serum creatinine concentration is affected by the GFR but is also affected by several factors that are independent of GFR, such as age, race, muscle mass, gender, medication use, and catabolic state (3). Moreover, different laboratories measure serum creatinine using different methods, giving results that are difficult to compare (5). The measurement of urinary creatinine clearance overcomes some of the limitations of serum creatinine but remains inaccurate because of collection errors and changes in creatinine excretion (5). Various creatinine-based equations have been developed in an attempt to improve the estimation of GFR from serum creatinine (5). These equations, however, have not been shown to be accurate in renal transplant recipients, and their suitability in clinical trials has been called into question (6,7).
Serum cystatin C is a low molecular weight protein that functions as a cysteine protease inhibitor and is produced at a constant rate by all nucleated cells (8). In the kidney, it is freely filtered and catabolized in the proximal tubule without being secreted (8). Studies to date suggest that cystatin C is a better marker of GFR than serum creatinine (9). Until recently, however, studies that have evaluated cystatin C have used the serum concentration rather than an estimate of GFR based on the measured concentration. Several prediction equations have been derived from both pediatric and adult patients to estimate GFR from the serum cystatin C concentration (1013). However, only one (14) has been validated in a separate cohort of adult renal transplant recipients. Accordingly, the objective of this study was to estimate GFR from the serum cystatin C concentration using four published equations in an independent sample of adult renal transplant recipients. The bias, precision, and accuracy of the prediction equations were compared with radioisotopic GFR reference measurement. A similar assessment of creatinine-based prediction equations was also performed to determine whether cystatin C had any advantage over serum creatinine at the estimation of GFR.
| Materials and Methods |
|---|
|
|
|---|
Laboratory Assessment
GFR was measured by the plasma clearance of radiolabeled diethylenetriaminepentaacetic acid (99mTc-DTPA) (15,16). Ten millicuries (370 Mbq) of 99mTc-DTPA was given as a single injection with plasma samples drawn at 120, 180, and 240 min after injection (17,18). To ensure reliability of the 99mTc-DTPA measurements, we performed standard radiochemical and radiopharmaceutical purity tests on each preparation of 99mTc-DTPA. The product specification was set at 95% purity, but the average purity that was obtained from our radiopharmacy laboratory was approximately 99% pure. In addition, the well counter was verified weekly for count reproducibility. The GFR was corrected for standard body surface area by multiplying the measured value by 1.73 and dividing by the patients body surface area as estimated by the DuBois formula (19). On the day of the 99mTc-DTPA GFR measurement, patients were weighed; had their height measured; had a blood sample taken for serum creatinine, urea, cystatin C, and albumin; and provided a 24-h urine collection for the measurement of creatinine. Gender, race, age, medication use, cause of renal failure and number of transplants was recorded.
The serum creatinine was measured using the modified Jaffe reaction on a Beckman Coulter LX20 Pro Clinical System using manufacturers reagents (Beckman Coulter Inc., Brea, CA). The coefficient of variation for serum creatinine was 4.9% at 0.6 mg/dl (55 µmol/L), 1.7% at 1.7 mg/dl (150 µmol/L), and 1.3% at 6.8 mg/dl (600 µmol/L). Cystatin C was measured using an N Latex cystatin C kit (Dade Behring, Mississauga, Canada) on a Behring BN ProSpec analyzer (Dade Behring, Marburg, Germany). The coefficient of variation of serum cystatin C was 3.1% at 1.06 mg/L, 3.5% at 2.04 mg/L, and 6.7% at 5.26 mg/L.
The use of serum creatinine in the equation derived from the Modification of Diet in Renal Disease (MDRD) study requires that the creatinine be calibrated to the laboratory that developed the equation (5,20). To calibrate the Ottawa Hospital serum creatinine, we sent 50 samples (range 0.6 to 4.0 mg/dl) to the Cleveland Clinic laboratory, which performed the creatinine measurements for the MDRD study (5). Overall, there was excellent agreement between both laboratories (correlation coefficient 0.989). The Ottawa Hospital serum creatinine was calibrated as recommended (5), and the calibrated serum creatinine values were used in the MDRD prediction equations. The calibrated creatinine was calculated as follows: 1.076 (Ottawa Hospital serum creatinine) 0.082
GFR was estimated with seven equations that used serum creatinine (15,2126) and four equations that used cystatin C (1013) (Tables 1 and 2). The prediction equations that were not expressed as ml/min per 1.73 m2 (13,21,24,25) were adjusted by multiplying the value by 1.73 and dividing by the patients body surface area as estimated by the DuBois formula (19). The creatinine was measured in the 24-h urine collection, and the creatinine clearance was calculated using the standard formula (27). The creatinine clearance was corrected for body surface area as described above.
|
|
60 ml/min per 1.73 m2) and gender. Calculations were performed using an Excel spreadsheet. | Results |
|---|
|
|
|---|
|
|
|
|
60 ml/min per 1.73 m2. The Filler and Le Bricon equations remained accurate when the estimated GFR was either above or below 60 ml/min per 1.73 m2. The Filler equation was the most accurate formula when the estimated GFR was
60 ml/min per 1.73 m2, with 56% of estimates within 10% of the measured GFR (Table 6). The Le Bricon equation was the most accurate formula when the estimated GFR was <60 ml/min per 1.73 m2, with 36% of estimates within 10% of the measured GFR (Table 6). Tables 7 and 8 show the performance of the GFR estimates stratified by gender. In general, the bias was lower and the accuracy was higher in women compared with men. However, the Filler and Le Bricon equations had nearly identical measures of accuracy in both male and female patients (Tables 7 and 8).
|
|
|
| Discussion |
|---|
|
|
|---|
The findings of this study are clinically relevant given the previous research that evaluated renal function in kidney transplant recipients. Mariat et al. (7), Gaspari et al. (6), and Poge et al. (28) evaluated the performance of creatinine-based equations in renal transplant recipients. The accuracy of the creatinine-based equations was variable among the three studies. However, it should be noted that the methods used to measure serum creatinine differed in the studies (6,7,28). In addition, evaluation of the MDRD equation requires calibration of the serum creatinine to the laboratory used in the MDRD study (20), which was not done in these studies (6,7,28). In a recent study that evaluated markers of renal function in 29 kidney transplant recipients, Risch and Huber (14) used a calibrated serum creatinine to estimate GFR using the MDRD equation. Using the calibrated serum creatinine, they found that 66% of estimates were within 30% of the measured GFR (14). In our study, we showed similar accuracy of the MDRD equation using a calibrated serum creatinine.
Cystatin C has been studied to a limited extent in renal transplantation. Risch et al. (29) compared cystatin C with measured GFR in 30 renal transplant recipients. Using receiver operating characteristic curves, they showed that cystatin C had greater diagnostic accuracy than creatinine at detecting GFR <60 ml/min. Christensson et al. (30) measured cystatin C and iohexol clearance in 125 renal transplant patients. They found that cystatin C was significantly more sensitive than the serum creatinine in the ability to detect a fall in the GFR <60 ml/min. However, they found no difference in the area under the receiver operating characteristic curves for cystatin C (0.94) and serum creatinine (0.90), suggesting that there was no real difference in diagnostic accuracy (30). These studies were limited by the use of the serum cystatin C concentration rather than an estimate of GFR based on the measured concentration.
In the previously mentioned study by Risch and Huber (14), GFR was estimated using one cystatin Cbased equation. They found that the estimated GFR from the cystatin Cbased Larsson equation had a bias of 4.7 ml/min per 1.73 m2 and that 69% of estimates were within 30% of the measured GFR (14). These results were substantially better than the performance of the Larsson equation in our study, which actually had the highest bias and lowest accuracy of all of the equations evaluated. These discrepant results are likely due to the different methods used to measure cystatin C and estimate GFR. Larsson et al. (13) published two separate equations to estimate GFR depending on which cystatin C assay was used. In the paper by Risch and Huber (14), cystatin C was measured using the Dako turbidimetric immunoassay, whereas we used the N Latex cystatin C kit by Dade Behring. Although Risch and Huber found the Dako-based Larsson equation to be more accurate than the Larsson equation that we used, it was far less accurate at estimating GFR than either the Filler or the Le Bricon equation.
The four cystatin Cbased prediction equations that we evaluated were derived in a variety of populations, including both adult and pediatric age groups as well as transplant and nontransplant patients (1013). The Le Bricon equation was derived from 25 adult renal transplant recipients (10), and the Filler equation was derived from 536 pediatric patients (12). These two equations, which were the most accurate in our study, were derived from populations thought to have lower muscle mass. It is possible that accuracy of the Filler and Le Bricon equations was due in part to the similarity between the populations from which the equations were derived and our study population. Although it has been reported that cystatin C is independent of factors such as age and weight, others have shown contradictory findings (31). In a study involving 8058 patients from the Netherlands, Knight et al. (31) showed that increasing age, male gender, increasing weight, current smoking, and higher C-reactive protein level were independently associated with a higher cystatin C concentration. These associations were independent of renal function as measured using urinary creatinine clearance (31). These findings suggest that cystatin C concentration may be influenced by factors other than renal function. This fact should be taken into consideration when interpreting our results.
Strengths of this study included the measurement of cystatin C, serum creatinine, and 99Tc-DTPA GFR on the same day to ensure that a similar degree of renal function was present when each measurement was made. The serum creatinine values all were measured at the same laboratory using the same method to avoid differences in calibration (5). In addition, our serum creatinine was calibrated to the Cleveland Clinic laboratory, which performed the creatinine measurements for the MDRD study. This allowed us to use a calibrated serum creatinine to estimate GFR with the MDRD equations as recommended (5,20).
Limitations to this study should be noted. First, the study population was predominantly made up of white patients and only 2.6% of the patients were black. Although cystatin C concentrations have been shown to be independent of race (32,33), firm conclusions about the accuracy of the cystatin C equations in black, Asian, and other populations cannot be made with our data. Second, all of our patients were on low-dose steroids as they were clinically stable. Cystatin C is influenced by high-dose steroids (34); as such, our data cannot be used to support the use of cystatin C to monitor renal function in the setting of high-dose steroid use (e.g., allograft rejection). Whether low-dose steroids increase cystatin C levels remains unclear. Risch et al. (35) showed that renal transplant recipients on low-dose prednisone (5 to 10 mg/d) had a higher cystatin C concentration compared with those on steroid-free immunosuppression. In contrast, Bökenkamp et al. (36) found that pediatric renal transplant recipients had higher cystatin C concentrations compared with other children with nontransplant renal disease, but there was no correlation between cystatin C and steroid dose. Third, we did not simultaneously measure thyroid function to rule out hypothyroidism or hyperthyroidism, which both are known to influence cystatin C concentration (37). However, in this stable population of renal transplant recipients with close medical follow-up, it would be unlikely that a significant number would have unrecognized thyroid dysfunction. Fourth, we measured cystatin C only once in each study participant. There is some controversy about the intrapatient variability of cystatin C with a study in healthy volunteers showing a higher coefficient of variation for cystatin C compared with creatinine (38), whereas a recent study in pediatric renal transplant patients did not confirm this (39). The intrapatient variability of cystatin C in adult renal transplant patients has not been assessed. It is plausible that a high coefficient of variation could be seen in the adult transplant population, making cystatin C an impractical marker for long-term follow-up. This issue will require further study in renal transplant recipients. Fifth, only three patients had stage 5 chronic kidney disease; thus, no conclusions about the accuracy of the prediction equations at this level of function can be made from our data. Finally, although we used a calibrated serum creatinine for the MDRD equation, calibration for the other creatinine-based equations (Cockcroft-Gault, Nankivell, Walser, Jelliffe, and Mawer) and cystatin C was not done. This may account for some of the bias that we found in these other equations. In addition, it is not known whether calibration is an important issue with cystatin C, but it may become relevant with future use of these prediction equations.
In conclusion, this analysis has shown that GFR can be estimated accurately in renal transplant recipients using the cystatin Cbased prediction equations of Filler and Le Bricon. We have also confirmed that cystatin Cbased estimates of GFR are more accurate than traditional creatinine-based equations. Further prospective studies with repetitive measurement of cystatin C are needed to determine whether cystatin Cbased estimates of GFR will be sufficiently accurate to monitor long-term allograft function.
| Acknowledgments |
|---|
We thank the staff and patients from the renal transplant program who participated in the study. We acknowledge Alan Thibeau, Nur Jamal, Ian Graham, Lisa Banfield, Sheila Dowell, Philip St. Laurent, Julie Noel, Elyse Bienvenue, Martine Blouin, Claudine Messier, and Sunil Thakrar for assistance with the DTPA GFR measurements; Marcella Cheng-Fitzpatrick for data management; and Amy Pocock, Lisa South, Judy Cheesman, Darlene Hackett, Margo McCoshen, and Paul McLoughlin for invaluable assistance in conducting this study.
| Footnotes |
|---|
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
C. P. Reinhardt, M. J. Germain, E. V. Groman, J. G. Mulhern, R. Kumar, and D. E. Vaccaro Functional immunoassay technology (FIT), a new approach for measuring physiological functions: application of FIT to measure glomerular filtration rate (GFR) Am J Physiol Renal Physiol, November 1, 2008; 295(5): F1583 - F1588. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Poge, T. Gerhardt, and R. P. Woitas Estimation of Glomerular Filtration Rate by Use of Beta-Trace Protein Clin. Chem., August 1, 2008; 54(8): 1403 - 1405. [Full Text] [PDF] |
||||
![]() |
C. Mariat, N. Maillard, M. Phayphet, L. Thibaudin, S. Laporte, E. Alamartine, and F. Berthoux Estimated glomerular filtration rate as an end point in kidney transplant trial: where do we stand? Nephrol. Dial. Transplant., January 1, 2008; 23(1): 33 - 38. [Full Text] [PDF] |
||||
![]() |
N. Kasitanon, D.M. Fine, M. Haas, L.S. Magder, and M. Petri Estimating renal function in lupus nephritis: comparison of the Modification of Diet in Renal Disease and Cockcroft Gault equations Lupus, November 1, 2007; 16(11): 887 - 895. [Abstract] [PDF] |
||||
![]() |
C. A. White, A. Akbari, S. Doucette, D. Fergusson, N. Hussain, L. Dinh, G. Filler, N. Lepage, and G. A. Knoll A Novel Equation to Estimate Glomerular Filtration Rate Using Beta-Trace Protein Clin. Chem., November 1, 2007; 53(11): 1965 - 1968. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. White, A. Akbari, N. Hussain, L. Dinh, G. Filler, N. Lepage, and G. A. Knoll Chronic kidney disease stage in renal transplantation classification using cystatin C and creatinine-based equations Nephrol. Dial. Transplant., October 1, 2007; 22(10): 3013 - 3020. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |